Drug intelligence / Profile preview

ST-1830

Development stage: Preclinical
Lead developer: Beijing Scitech-Mq Pharmaceuticals
Modality: Small Molecules

Overview

ST-1830 is a small molecule modulator of immune and inflammatory targets currently under development by Beijing Scitech-Mq Pharmaceuticals. It is being investigated for the treatment of various autoimmune and inflammatory conditions, including psoriasis, sepsis, Crohn's disease, ulcerative colitis, and rheumatoid arthritis. As of the latest pipeline updates, the drug is in the preclinical and IND-enabling stages of development. The specific molecular targets within the immune system have not been publicly disclosed by the developer, though it is categorized as a modulator of immune and inflammatory pathways.

Beyond the preview

Go deeper on ST-1830.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ST-1830.

Explore the full profile